Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597701 · ClinicalTrials.gov registry record · NA
Treating Alcohol Withdrawal With Oral Baclofen
A NA study, sponsored by Essentia Health.
- Completed
- Registry status
- NA
- Development phase
- 79
- Enrollment target
NCT00597701 is a NA study that has completed, run by Essentia Health. The registered enrollment target is 79 participants.
The verdict
NCT00597701, a NA study, has completed, sponsored by Essentia Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is determine if subjects with alcohol withdrawal who receive oral baclofen, plus standard benzodiazepine therapy, will experience less severe withdrawal symptoms than those who receive placebo plus standard benzodiazepine therapy.Subjects with alcohol withdrawal syndrome(AWS)who receive baclofen plus standard benzodiazepine therapy will experience fewer complications of AWS (as measured by use of additional sedatives, restraints, and/or intensive care unit \[ICU\] admissions) compared with subjects who receive placebo plus standard benzodiazepine therapy.
Interventions
- DRUG Placebo
- DRUG Lorazepam
- DRUG Baclofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2003-04 |
| Est. Completion | 2008-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00597701
The ClinicalTrials.gov registry entry for NCT00597701 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Essentia Health, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00597701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00597701 about?
NCT00597701 is a clinical study titled "Treating Alcohol Withdrawal With Oral Baclofen". The purpose of this study is determine if subjects with alcohol withdrawal who receive oral baclofen, plus standard benzodiazepine therapy, will experience less severe withdrawal symptoms than those who receive placebo plus standard benzodiazepine therapy.Subjects with alcohol withdrawal syndrome(AW...
What is the current status of trial NCT00597701?
This trial is currently completed. It is a NA study. The enrollment target is 79 participants. The study started on 2003-04. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00597701?
The interventions under investigation include: Placebo (DRUG), Lorazepam (DRUG), Baclofen (DRUG).
Who is sponsoring clinical trial NCT00597701?
This trial is sponsored by Essentia Health, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.